Halozyme Therapeutics Stock Current Valuation
| HALO Stock | USD 45.39 0.43 0.94% |
Valuation analysis of Halozyme Therapeutics helps investors to measure Halozyme Therapeutics' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. As of the 17th of May 2024, Enterprise Value Over EBITDA is likely to grow to 15.55. Also, Enterprise Value Multiple is likely to grow to 15.55. Fundamental drivers impacting Halozyme Therapeutics' valuation include:
Price Book 58.5485 | Enterprise Value 6.8 B | Enterprise Value Ebitda 13.431 | Price Sales 5.9156 | Forward PE 12.6263 |
Undervalued
Today
Please note that Halozyme Therapeutics' price fluctuation is very steady at this time. Calculation of the real value of Halozyme Therapeutics is based on 3 months time horizon. Increasing Halozyme Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Our valuation method for Halozyme Therapeutics is useful when determining the fair value of the Halozyme stock, which is usually determined by what a typical buyer is willing to pay for full or partial control of Halozyme Therapeutics. Since Halozyme Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Halozyme Stock. However, Halozyme Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 45.39 | Real 51.45 | Target 51.9 | Hype 45.39 | Naive 47.38 |
The real value of Halozyme Stock, also known as its intrinsic value, is the underlying worth of Halozyme Therapeutics Company, which is reflected in its stock price. It is based on Halozyme Therapeutics' financial performance, assets, liabilities, growth prospects, management team, or industry conditions. The intrinsic value of Halozyme Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Halozyme Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Halozyme Therapeutics helps investors to forecast how Halozyme stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Halozyme Therapeutics more accurately as focusing exclusively on Halozyme Therapeutics' fundamentals will not take into account other important factors: Halozyme Therapeutics Company Current Valuation Analysis
Halozyme Therapeutics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Halozyme Therapeutics Current Valuation | 6.85 B |
Most of Halozyme Therapeutics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Halozyme Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Halozyme Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Halozyme Therapeutics is extremely important. It helps to project a fair market value of Halozyme Stock properly, considering its historical fundamentals such as Current Valuation. Since Halozyme Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Halozyme Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Halozyme Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Halozyme Current Valuation Historical Pattern
Today, most investors in Halozyme Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Halozyme Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Halozyme Therapeutics current valuation as a starting point in their analysis.
Halozyme Therapeutics Current Valuation |
| Timeline |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Halozyme Therapeutics has a Current Valuation of 6.85 B. This is 52.34% lower than that of the Biotechnology sector and 47.37% higher than that of the Health Care industry. The current valuation for all United States stocks is 58.82% higher than that of the company.
Halozyme Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Halozyme Therapeutics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Halozyme Therapeutics could also be used in its relative valuation, which is a method of valuing Halozyme Therapeutics by comparing valuation metrics of similar companies.Halozyme Therapeutics is currently under evaluation in current valuation category among related companies.
Halozyme Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Halozyme Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Halozyme Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Halozyme Fundamentals
| Return On Equity | 2.62 | ||||
| Return On Asset | 0.13 | ||||
| Profit Margin | 0.37 % | ||||
| Operating Margin | 0.49 % | ||||
| Current Valuation | 6.85 B | ||||
| Shares Outstanding | 127.27 M | ||||
| Shares Owned By Insiders | 1.11 % | ||||
| Shares Owned By Institutions | 99.16 % | ||||
| Number Of Shares Shorted | 8.41 M | ||||
| Price To Earning | 60.08 X | ||||
| Price To Book | 58.55 X | ||||
| Price To Sales | 5.92 X | ||||
| Revenue | 829.25 M | ||||
| Gross Profit | 454.2 M | ||||
| EBITDA | 422.43 M | ||||
| Net Income | 281.59 M | ||||
| Cash And Equivalents | 209.36 M | ||||
| Cash Per Share | 1.52 X | ||||
| Total Debt | 1.5 B | ||||
| Debt To Equity | 4.28 % | ||||
| Current Ratio | 2.72 X | ||||
| Book Value Per Share | 1.40 X | ||||
| Cash Flow From Operations | 388.57 M | ||||
| Short Ratio | 9.75 X | ||||
| Earnings Per Share | 2.41 X | ||||
| Price To Earnings To Growth | (2.50) X | ||||
| Target Price | 51.78 | ||||
| Number Of Employees | 373 | ||||
| Beta | 1.26 | ||||
| Market Capitalization | 5.78 B | ||||
| Total Asset | 1.73 B | ||||
| Retained Earnings | 90.55 M | ||||
| Working Capital | 633.93 M | ||||
| Current Asset | 171.77 M | ||||
| Current Liabilities | 62.46 M | ||||
| Net Asset | 1.73 B |
About Halozyme Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Halozyme Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Halozyme Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Halozyme Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Halozyme Therapeutics Piotroski F Score and Halozyme Therapeutics Altman Z Score analysis. To learn how to invest in Halozyme Stock, please use our How to Invest in Halozyme Therapeutics guide.You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Complementary Tools for Halozyme Stock analysis
When running Halozyme Therapeutics' price analysis, check to measure Halozyme Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Halozyme Therapeutics is operating at the current time. Most of Halozyme Therapeutics' value examination focuses on studying past and present price action to predict the probability of Halozyme Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Halozyme Therapeutics' price. Additionally, you may evaluate how the addition of Halozyme Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Equity Valuation Check real value of public entities based on technical and fundamental data |
Is Halozyme Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Halozyme Therapeutics. If investors know Halozyme will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Halozyme Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.069 | Earnings Share 2.41 | Revenue Per Share 6.643 | Quarterly Revenue Growth 0.208 | Return On Assets 0.1348 |
The market value of Halozyme Therapeutics is measured differently than its book value, which is the value of Halozyme that is recorded on the company's balance sheet. Investors also form their own opinion of Halozyme Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Halozyme Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Halozyme Therapeutics' market value can be influenced by many factors that don't directly affect Halozyme Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Halozyme Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Halozyme Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Halozyme Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.